Novartis Says Early Addition of Cholesterol Drug Shows Positive Results in Trial
By Adria Calatayud
Novartis said new data from a late-stage clinical trial showed that early addition of its Leqvio drug reduced cholesterol in patients with atherosclerotic cardiovascular disease.
The Swiss pharmaceutical giant said Saturday that the phase 3 trial evaluated the effectiveness of adding Leqvio earlier compared to usual U.S. clinical practice.
It showed that early initiation with Leqvio led to a significant cholesterol reduction compared to usual care for patients with atherosclerotic cardiovascular disease who weren't able to achieve it on a therapy of statin--a class of cholesterol-reducing drugs--alone, the company said.
The safety profile of Leqvio was consistent with previous studies, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
April 08, 2024 01:47 ET (05:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year